ZA201805951B - Compounds and methods for modulating bruton's tyrosine kinase - Google Patents
Compounds and methods for modulating bruton's tyrosine kinaseInfo
- Publication number
- ZA201805951B ZA201805951B ZA2018/05951A ZA201805951A ZA201805951B ZA 201805951 B ZA201805951 B ZA 201805951B ZA 2018/05951 A ZA2018/05951 A ZA 2018/05951A ZA 201805951 A ZA201805951 A ZA 201805951A ZA 201805951 B ZA201805951 B ZA 201805951B
- Authority
- ZA
- South Africa
- Prior art keywords
- bruton
- modulating
- compounds
- methods
- tyrosine kinase
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307399P | 2016-03-11 | 2016-03-11 | |
| US201662342004P | 2016-05-26 | 2016-05-26 | |
| PCT/US2017/021966 WO2017156495A1 (en) | 2016-03-11 | 2017-03-10 | Compounds and methods for modulating bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201805951B true ZA201805951B (en) | 2020-12-23 |
Family
ID=59789888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/05951A ZA201805951B (en) | 2016-03-11 | 2018-09-05 | Compounds and methods for modulating bruton's tyrosine kinase |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10870652B2 (https=) |
| EP (1) | EP3426637B1 (https=) |
| JP (1) | JP6972002B2 (https=) |
| KR (1) | KR102416971B1 (https=) |
| CN (2) | CN109071455B (https=) |
| AU (1) | AU2017230098B2 (https=) |
| ES (1) | ES2912465T3 (https=) |
| IL (1) | IL261583A (https=) |
| MX (1) | MX388026B (https=) |
| PL (1) | PL3426637T3 (https=) |
| WO (1) | WO2017156495A1 (https=) |
| ZA (1) | ZA201805951B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071455B (zh) * | 2016-03-11 | 2022-08-02 | 嘉兴和剂药业有限公司 | 用于调节布鲁顿酪氨酸激酶的化合物及方法 |
| JOP20190113A1 (ar) * | 2016-11-18 | 2019-05-15 | Biocad Joint Stock Co | مثبطات بروتون تيروزين كيناز |
| WO2018175512A1 (en) * | 2017-03-22 | 2018-09-27 | Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| KR102384924B1 (ko) * | 2017-07-12 | 2022-04-08 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
| CN108191871B (zh) * | 2018-01-02 | 2020-02-18 | 成都倍特药业有限公司 | 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用 |
| CN111662232B (zh) * | 2019-03-06 | 2022-08-02 | 中国科学院上海药物研究所 | 具有2h-吲唑结构的小分子化合物及其合成和应用 |
| CN113544130B (zh) | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| WO2020252397A1 (en) * | 2019-06-12 | 2020-12-17 | Baylor College Of Medicine | Small molecule proteolysis-targeting chimeras and methods of use thereof |
| FI4036095T3 (fi) * | 2019-09-26 | 2024-02-14 | Jumbo Drug Bank Co Ltd | 4-Fluori-1H-pyratsolo[3,4-c]pyridiinijohdannaisia selektiivisinä Brutonin tyrosiinikinaasin (BTK) inhibiittoreina B-solulymfooman ja autoimmuunitautien hoitamiseksi |
| CN114437078A (zh) * | 2020-11-03 | 2022-05-06 | 海思科医药集团股份有限公司 | 一种降解btk的氘代物及其在医药上的应用 |
| CN117377675A (zh) * | 2021-06-01 | 2024-01-09 | 正大天晴药业集团股份有限公司 | 含有并环或螺环的布鲁顿酪氨酸激酶降解剂 |
| TW202321191A (zh) * | 2021-07-29 | 2023-06-01 | 美商賽迪拉治療股份有限公司 | Ｔｅａｄ抑制劑及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW502019B (en) * | 1999-03-26 | 2002-09-11 | Cocensys Inc | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| SE0301906D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| KR101417136B1 (ko) * | 2005-12-13 | 2014-08-07 | 머크 샤프 앤드 돔 코포레이션 | Ｅｒｋ 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물 |
| WO2007095223A2 (en) * | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| US20120101114A1 (en) * | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| CA2730930C (en) * | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| US8633318B2 (en) | 2008-09-16 | 2014-01-21 | Proximagen Ltd | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder |
| US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| KR101301533B1 (ko) | 2010-02-09 | 2013-09-04 | 한미사이언스 주식회사 | 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체 |
| JP2014520863A (ja) * | 2011-07-13 | 2014-08-25 | ファーマサイクリックス，インク． | Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| CN104080789B (zh) | 2012-01-31 | 2016-05-11 | 南京奥昭生物科技有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
| WO2014022569A1 (en) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| JP2016538270A (ja) | 2013-10-25 | 2016-12-08 | ファーマサイクリックス エルエルシー | 移植片対宿主病を処置し予防する方法 |
| WO2015124570A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of influenza a virus infection |
| EP3414234B1 (en) * | 2015-10-14 | 2022-06-29 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| KR102699906B1 (ko) * | 2016-01-21 | 2024-08-29 | 즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 | 브루톤 티로신 키나제 억제제 |
| CN109071455B (zh) * | 2016-03-11 | 2022-08-02 | 嘉兴和剂药业有限公司 | 用于调节布鲁顿酪氨酸激酶的化合物及方法 |
-
2017
- 2017-03-10 CN CN201780028799.7A patent/CN109071455B/zh active Active
- 2017-03-10 JP JP2018547964A patent/JP6972002B2/ja active Active
- 2017-03-10 AU AU2017230098A patent/AU2017230098B2/en active Active
- 2017-03-10 EP EP17764260.0A patent/EP3426637B1/en active Active
- 2017-03-10 MX MX2018010971A patent/MX388026B/es unknown
- 2017-03-10 CN CN202210903642.7A patent/CN115746000A/zh active Pending
- 2017-03-10 PL PL17764260T patent/PL3426637T3/pl unknown
- 2017-03-10 US US16/083,409 patent/US10870652B2/en active Active
- 2017-03-10 KR KR1020187029381A patent/KR102416971B1/ko active Active
- 2017-03-10 WO PCT/US2017/021966 patent/WO2017156495A1/en not_active Ceased
- 2017-03-10 ES ES17764260T patent/ES2912465T3/es active Active
-
2018
- 2018-09-04 IL IL261583A patent/IL261583A/en unknown
- 2018-09-05 ZA ZA2018/05951A patent/ZA201805951B/en unknown
-
2020
- 2020-08-27 US US17/004,943 patent/US11306099B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018010971A (es) | 2019-03-28 |
| CA3017567A1 (en) | 2017-09-14 |
| KR20180133415A (ko) | 2018-12-14 |
| AU2017230098B2 (en) | 2021-03-25 |
| CN115746000A (zh) | 2023-03-07 |
| WO2017156495A8 (en) | 2018-09-27 |
| ES2912465T3 (es) | 2022-05-26 |
| EP3426637A4 (en) | 2019-09-18 |
| US20190106423A1 (en) | 2019-04-11 |
| EP3426637B1 (en) | 2022-02-09 |
| US10870652B2 (en) | 2020-12-22 |
| MX388026B (es) | 2025-03-19 |
| US11306099B1 (en) | 2022-04-19 |
| WO2017156495A1 (en) | 2017-09-14 |
| NZ745927A (en) | 2024-05-31 |
| KR102416971B1 (ko) | 2022-07-04 |
| CN109071455B (zh) | 2022-08-02 |
| AU2017230098A1 (en) | 2018-09-20 |
| EP3426637A1 (en) | 2019-01-16 |
| CN109071455A (zh) | 2018-12-21 |
| PL3426637T3 (pl) | 2022-05-30 |
| JP6972002B2 (ja) | 2021-11-24 |
| IL261583A (en) | 2018-10-31 |
| JP2019507793A (ja) | 2019-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201805951B (en) | Compounds and methods for modulating bruton's tyrosine kinase | |
| ZA201903932B (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
| ZA201805439B (en) | Bruton's tyrosine kinase inhibitors | |
| IL255831A (en) | Inhibitors of bruton's tyrosine kinase | |
| EP3177366A4 (en) | Bruton's tyrosine kinase inhibitor combinations and uses thereof | |
| ZA201903071B (en) | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | |
| EP3138842A4 (en) | Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors | |
| EP3174539A4 (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
| IL245042A0 (en) | Treatment with proton tyrosine kinase inhibitors and immunotherapy | |
| EP3220912A4 (en) | Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations | |
| IL253995A0 (en) | Pharmaceutical formulations of proton tyrosine kinase inhibitor | |
| IL250085A0 (en) | New compounds of proton tyrosine kinase inhibitor | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| EP3141546A4 (en) | Inhibitor of bruton's tyrosine kinase | |
| EP3159340A4 (en) | New bruton's tyrosine kinase inhibitor | |
| IL244492A0 (en) | Broton tyrosine kinase inhibitors | |
| IL259863B (en) | Polycyclic compounds as inhibitors of proton tyrosine kinase | |
| IL259862B (en) | Inhibitors of proton tyrosine kinase and methods of using them | |
| ZA201707867B (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| SG10202013034QA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| EP3273961A4 (en) | Solvated forms of a bruton's tyrosine kinase inhibitor | |
| EP3328380A4 (en) | INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF | |
| SI3353164T1 (sl) | Bi-heteroaril substituiran 1,4-benzodiazepini in njihove uporabe za zdravljenje raka | |
| EP3113779A4 (en) | Methods of treating a bruton's tyrosine kinase disease or disorder |